Infectious diseases now · 2025
Standard- versus high-dose tigecycline in pneumonia due to carbapenem-resistant Acinetobacter baumannii: A propensity score-matched retrospective study.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Özgen-Top Özge, Aysert-Yildiz Pınar, Tekin-Taş Zeynep, Arslan Şeyma, Erkan Emincan, Özcan Fatma Zehra, Şahin Elif Ayça, Dizbay Murat
Аннотация
OBJECTIVES: This study aimed to compare the effectiveness and safety of standard-dose and high-dose tigecycline in pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB).
METHODS: This retrospective, propensity score-matched study, conducted between January 2018 and April 2023, included adult patients with CRAB pneumonia who received tigecycline for at least five days. Patients were categorized into standard-dose (100 mg loading dose, followed by 2x50mg) and high-dose (200 mg loading dose, followed by 2x100mg) groups. Propensity score matching was performed to minimize baseline differences between groups. After matching, factors associated with 30-day mortality were evaluated using conditional logistic regression. Clinical and microbiological success and adverse events were compared.
RESULTS: A total of 170 patients were analyzed, including 69 in the standard-dose and 101 in the high-dose group. After matching, 62 patients remained in each group. Clinical success was 48.3 % in the standard-dose and 40.4 % in the high-dose group (p = 0.406). Seven-day and 30-day mortality were 8.1 % vs. 11.3 % (p = 0.544) and 43.5 % vs. 56.5 % (p = 0.151), respectively. Microbiological success was higher with high-dose tigecycline (50.9 % vs. 26.5 %, p = 0.012). In multivariate analysis, only the SOFA score independently predicted 30-day mortality (aOR 1.73, 95 % CI 1.09-2.76). Adverse events, particularly elevations in liver enzymes, bilirubin, and thrombocytopenia, were more frequent in the high-dose group.
CONCLUSION: High-dose tigecycline improved microbiological eradication but did not enhance survival or clinical outcomes and was associated with greater toxicity. These findings support cautious use of high-dose tigecycline in CRAB pneumonia pending randomized controlled trials.
METHODS: This retrospective, propensity score-matched study, conducted between January 2018 and April 2023, included adult patients with CRAB pneumonia who received tigecycline for at least five days. Patients were categorized into standard-dose (100 mg loading dose, followed by 2x50mg) and high-dose (200 mg loading dose, followed by 2x100mg) groups. Propensity score matching was performed to minimize baseline differences between groups. After matching, factors associated with 30-day mortality were evaluated using conditional logistic regression. Clinical and microbiological success and adverse events were compared.
RESULTS: A total of 170 patients were analyzed, including 69 in the standard-dose and 101 in the high-dose group. After matching, 62 patients remained in each group. Clinical success was 48.3 % in the standard-dose and 40.4 % in the high-dose group (p = 0.406). Seven-day and 30-day mortality were 8.1 % vs. 11.3 % (p = 0.544) and 43.5 % vs. 56.5 % (p = 0.151), respectively. Microbiological success was higher with high-dose tigecycline (50.9 % vs. 26.5 %, p = 0.012). In multivariate analysis, only the SOFA score independently predicted 30-day mortality (aOR 1.73, 95 % CI 1.09-2.76). Adverse events, particularly elevations in liver enzymes, bilirubin, and thrombocytopenia, were more frequent in the high-dose group.
CONCLUSION: High-dose tigecycline improved microbiological eradication but did not enhance survival or clinical outcomes and was associated with greater toxicity. These findings support cautious use of high-dose tigecycline in CRAB pneumonia pending randomized controlled trials.